Fresh analysis suggests that patients who discontinue popular GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who stop conventional diet and exercise plans.
Published data in a leading medical journal shows that while obese people frequently drop substantial amounts of their total mass while on the medication, the weight is regained at an average rate of nearly a kilo each month after stopping.
"Users buying such drugs should be aware of the danger of fast rebound weight gain when the medication ends," warns expert Dr. Susan Jebb.
That rate of recovery implies a reversion to original mass in about one and a half years.
Comparing Treatments
The study, which reviewed dozens of trials involving over 9,000 of participants, contrasted the outcomes of these new drugs with other pills.
Researchers point out that people who shed pounds through dieting generally experience a more gradual creep back—perhaps 100 grams monthly—post-intervention.
Explaining the Rapid Rebound
Doctors propose the mechanism of the drugs explains the heightened weight return.
GLP-1 drugs mimic a body's own chemical called GLP-1, which moderates appetite.
"Long-term administration of the hormone levels several times higher than the body's typical production could lead to the system to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this hormone supplement leads to hunger is no longer kept in check, making overeating much more probable."
A Chronic Disease?
Health authorities advise the injections for individuals with obesity-related health risks, alongside prescribed lifestyle changes.
Many experts say that, considering the likelihood of relapse, the therapy should be considered long-term.
This perspective is reinforced by drug manufacturers, who note that the results "highlight the chronic character of excess weight," akin to managing diseases like hypertension.
Patient Testimonies
Individuals who have stopped the jabs describe a powerful return of cravings.
"I experienced a trigger activating and I was suddenly extremely hungry," said a patient.
This difficulty is compounded if patients have not established sustainable lifestyle or habit modifications during therapy.
Growing Use
Recent estimates show that millions of adults in the UK have tried these injections in the past year, with demand remaining high.
- Use is greater among females compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
In conclusion, researchers emphasize that while these medications are potent tools for weight loss, they are not a standalone cure and maintained weight loss relies on combined lifestyle changes.
